Replies to post #8922 on BioSante Pharmaceuticals, Inc. (BPAX)

[PennyStockInvestor]

Explain more about this BPAX phase 3 trial for Parkinson. I don't think very many people on the message board know about any of this.
Ceregene (privately owned company) was once part of Cell Genesys which Biosante bought out in 2009 and by process of elimination the product that makes the most sense to purchase would be Ceregene's CRE 120 used to combat Parkinson Disease. It has completed Phase 2 trials and would be ready to go straight to phase III possibly with the support of the Michael J. Fox foundation.

Note: Simes sits on Ceregene's board of directors.

CRE 120 trial

Realize that this is just conjecture. The announcement of Bio-t-Gel approval followed by the phase 3 trial for Parkinson would give a big pop.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=71998389

[dionnfr]

Remember TEVA has to make the initial announcement

[Just the facts maam]

Just realized that there is a phase 2b to the Parkinson Disease CRE 120 trials still ongoing. Therefore if this is the target of their acquisition Phase III may not start until 2013 or 2014

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

[Just the facts maam]

Another possible acquisition would be Cold Genesys or the product they have in phase II/III trial. This product was originally owned by Biosante

Efficacy Study of Recombinant Adenovirus for Patients With Resistant Superficial Bladder Cancer (BOND)

Purpose
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of local cancer cell death and destroy tumor cells that has traveled to distant places as well as to surrounding lymph nodes.

Phase II/III trial

Interestingly the trial was updated Feb 7th, 2012 and the start date is April 2012. (Good timing)